載入中
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
前收盤價
US$135.28
+US$0.81 · +0.60%
盤中時間採用ET。市場資料可能有所延遲。
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
日內區間
目前US$135.28
52週區間
目前US$135.28
盤中時間採用ET。市場資料可能有所延遲。
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
日內區間
目前US$135.28
52週區間
目前US$135.28
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 27.08億 USD | 20.72億 USD | 16.97億 USD | 13.05億 USD | 10.99億 USD |
| 銷貨成本 | 7.68億 USD | 6.26億 USD | 5.37億 USD | 5億 USD | 3.47億 USD |
| 毛利 | 19.4億 USD | 14.46億 USD | 11.6億 USD | 8.06億 USD | 7.52億 USD |
| 研究與開發 | 3.01億 USD | 2.2億 USD | 2.05億 USD | 1.8億 USD | 1.6億 USD |
| 銷售、一般及管理費用 | 11.65億 USD | 9.17億 USD | 7.35億 USD | 5.88億 USD | 4.66億 USD |
| 營業費用 | 14.66億 USD | 11.37億 USD | 9.4億 USD | 7.68億 USD | 6.26億 USD |
| 利息收入 | 3470萬 USD | 3950萬 USD | 2860萬 USD | 930萬 USD | 50萬 USD |
| 利息支出 | 7970萬 USD | 4270萬 USD | 3620萬 USD | 3600萬 USD | 6170萬 USD |
| 折舊和攤銷 | 9040萬 USD | 8080萬 USD | 7280萬 USD | 6320萬 USD | 5740萬 USD |
| 營業利益 | 4.74億 USD | 3.09億 USD | 2.2億 USD | 3760萬 USD | 1.26億 USD |
| 淨利 | 2.47億 USD | 4.18億 USD | 2.06億 USD | 460萬 USD | 1680萬 USD |
公司資料更新於 2026年10月12日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$182.35
上漲空間 34.79%報告持有此股票曝險的交易所交易基金。
State Street SPDR S&P 500 ETF1557.T180.49億0.01%129.43兆 JPY0.09%¥122,850+0.12%
Vanguard Morningstar Total Stock Market ETFVTI3.28億0.01%2.3兆 USD0.03%US$381.94+0.63%
Vanguard S&P 500 ETFVOO2.73億0.02%1.8兆 USD0.03%US$715.59+0.61%
Vanguard Morningstar Small-Cap ETFVB2.37億0.13%1853億 USD0.03%US$289.48+0.64%
Invesco S&P 500 Equal Weight ETFRSP1.93億0.20%977.83億 USD0.20%US$213.04+0.55%
Vanguard Morningstar Small-Cap Growth ETFVBK1.36億0.30%447億 USD0.05%US$344.74+1.22%
iShares Core S&P 500 ETFIVV1.24億0.01%8964.4億 USD0.03%US$781.97+0.60%
State Street SPDR S&P 500 ETFSPY1.14億0.01%8172億 USD0.09%US$778.57+0.60%State Street SPDR S&P 500 ETF1557.TVanguard Morningstar Total Stock Market ETFVTIVanguard S&P 500 ETFVOOVanguard Morningstar Small-Cap ETFVBInvesco S&P 500 Equal Weight ETFRSPVanguard Morningstar Small-Cap Growth ETFVBKiShares Core S&P 500 ETFIVVState Street SPDR S&P 500 ETFSPYAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
